Dr. Nicholas Vogelzang was a renowned physician and researcher known for his pioneering work in the field of Genitourinary (GU) Oncology. He was dedicated to researching and treating rare forms of cancer and was known for his warmth, caring nature, professionalism, and vast knowledge. He provided extraordinary leadership in the development of clinical trials and therapeutics for cancer patients.

Dr. Vogelzang led multiple groundbreaking clinical trials aimed at identifying new therapies and treatment approaches for cancer patients, specifically investigating new therapies for GU cancers such as metastatic kidney cancer, prostate cancer, and metastatic bladder cancer, as well as mesothelioma. He helped organize GU oncologists, working to ensure that the field would have the necessary multi-disciplinary emphasis. He was particularly proud of the accomplishments of young investigators and those whose careers and research successes he had helped nurture over the years in treating GU cancers.

Dr. Vogelzang served as Professor of Medicine and Urologic Surgery at the University of Chicago and as Chair of Genitourinary Oncology as well as Director for the University of Chicago Cancer Research Center. He became the first editor of the Textbook of Genitourinary Oncology, the first major textbook to focus on the field of GU oncology from the combined perspectives of the molecular biologist, pathologist, oncologist, and urologist and remained its lead editor until recently.

In 2004, Dr. Vogelzang moved to Nevada and became Head of Genitourinary Oncology and Clinical Professor of Medicine for the University of Nevada School of Medicine in Las Vegas and Reno. He joined Comprehensive Cancer Centers of Nevada (CCCN) in 2009 as a medical oncologist and became the Director of the Nevada Cancer Institute. He also served as the Chair and Medical Director of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research.

Dr. Vogelzang passed away on September 20th, 2022.